Previous 10 | Next 10 |
-Preliminary data from 103 patients in the expansion portion of a Phase 1b clinical trial demonstrated the drug was well tolerated and anti-tumor activity was noted - Unique opportunity to leverage CELsignia platform to advance development of a first-in-class targeted therapy - ...
Celcuity (CELC) announces a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NVS), and Puma Biotechnology (PBYI), to conduct a Phase II clinical trial to evaluate the efficacy and safety of two targeted therapies in certain patients with metastatic HER2-...
- Trial will evaluate the efficacy and safety of Novartis’ targeted therapy TABRECTA ® and Puma’s NERLYNX ® in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test - This is Celcuity&...
MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3 rd generation diagnostics and expanded therapeutic options for cancer patients, today announced the closing, on February ...
Gainers: Sunesis Pharmaceuticals (SNSS) +38%, Owens & Minor (OMI) +32%, Salarius Pharmaceuticals (SLRX) +20%, Poseida Therapeutics (PSTX) +20%, PRA Health Sciences (PRAH) +19%.Losers: Rafael (RFL) -12%, Constellation Pharmaceuticals (CNST)...
Celcuity (CELC) traded 7.8% down premarket after pricing its now upsized underwritten public offering (earlier $20M in shares) of 1.71M shares at $14/share for gross proceeds of ~$24M.Underwriters granted 30-day option to purchase up to an additional 257.1K shares.Net proceeds to be...
MINNEAPOLIS, MN / ACCESSWIRE / February 24, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3 rd generation diagnostics and expanded therapeutic options for cancer patients, today announced the pricing of its pr...
MINNEAPOLIS, MN / ACCESSWIRE / February 22, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3 rd generation diagnostics and expanded therapeutic options for cancer patients, today announced that it has commenced...
Announced a clinical trial collaboration in December with Massachusetts General Hospital, UCLA, and Vanderbilt and Puma Biotechnology to conduct a Phase II clinical trial. In January, announced a clinical trial collaboration with Sarah Cannon Research Institute and Pfizer Inc. to condu...
MINNEAPOLIS, MN / ACCESSWIRE / February 1, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...